EA199900914A1 - Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective modulators of estrogen receptors - Google Patents

Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective modulators of estrogen receptors

Info

Publication number
EA199900914A1
EA199900914A1 EA199900914A EA199900914A EA199900914A1 EA 199900914 A1 EA199900914 A1 EA 199900914A1 EA 199900914 A EA199900914 A EA 199900914A EA 199900914 A EA199900914 A EA 199900914A EA 199900914 A1 EA199900914 A1 EA 199900914A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
prostate cancer
benign prostatic
prostatic hyperplasia
prophylaxis
Prior art date
Application number
EA199900914A
Other languages
Russian (ru)
Inventor
Блэйк Ли Нюбоер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199900914A1 publication Critical patent/EA199900914A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Abstract

Данное изобретение предлагает способ лечения или профилактики доброкачественной гиперплазии простаты или рака простаты у пациента, нуждающегося в таком лечении, включающий в себя введение селективно модулирующего рецепторы эстрогена соединения формулы (I)где Rи Rнезависимо представляют собой гидрокси и алкокси, содержащий от одного до четырех атомов углерода, Rи Rнезависимо представляют собой метил или этил, или Rи R, взятые вместе с атомом азота, к которому они присоединены, образуют пирролидиновое, метилпирролидиновое, диметилпирролидиновое, пиперидиновое, морфолиновое или гексаметилениминовое кольцо.Международная заявка была опубликована вместе с отчетом о международном поиске.This invention provides a method of treating or preventing benign prostatic hyperplasia or prostate cancer in a patient in need of such treatment, including administering estrogen receptor modulatory estrogen receptor compounds of formula (I) , R and R independently represent methyl or ethyl, or R and R, taken together with the nitrogen atom to which they are attached, form pyrrolidine, methyl pyrrolidine, dimethyl pyrrolide new, piperidino, morpholino or geksametileniminovoe koltso.Mezhdunarodnaya application was published together with the international search report.

EA199900914A 1997-04-09 1998-04-07 Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective modulators of estrogen receptors EA199900914A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4322397P 1997-04-09 1997-04-09
PCT/US1998/007274 WO1998045288A1 (en) 1997-04-09 1998-04-07 Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
EA199900914A1 true EA199900914A1 (en) 2000-04-24

Family

ID=21926126

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900914A EA199900914A1 (en) 1997-04-09 1998-04-07 Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective modulators of estrogen receptors

Country Status (16)

Country Link
EP (1) EP0975629A4 (en)
JP (1) JP2001518900A (en)
KR (1) KR20010006218A (en)
CN (1) CN1259944A (en)
AU (1) AU6966198A (en)
BR (1) BR9808515A (en)
CA (1) CA2286204A1 (en)
EA (1) EA199900914A1 (en)
HU (1) HUP0003589A3 (en)
ID (1) ID24358A (en)
IL (1) IL132277A0 (en)
NO (1) NO994903L (en)
PL (1) PL336205A1 (en)
TR (1) TR199902701T2 (en)
WO (1) WO1998045288A1 (en)
ZA (1) ZA982819B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
EP1392304A1 (en) * 2001-05-10 2004-03-03 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostate cancer
BRPI0712103A2 (en) * 2006-05-22 2012-01-17 Hormos Medical Corp method of treating chronic non-bacterial prostatitis and to prevent the progression of benign prostatic hyperplasia (bph) or prostate cancer in men
NZ585389A (en) 2007-10-16 2011-10-28 Repros Therapeutics Inc Trans-clomiphene for metabolic syndrome
MX2014009322A (en) 2012-02-29 2014-11-10 Repros Therapeutics Inc Combination therapy for treating androgen deficiency.
PT2958907T (en) 2013-02-19 2018-03-23 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
WO2017081171A1 (en) 2015-11-10 2017-05-18 Paracrine Therapeutics Ab Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429922A (en) * 1988-03-09 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for distinguishing virulent and non-virulent toxoplasma infections
IL132952A (en) * 1995-02-28 2002-02-10 Lilly Co Eli Benzothiophene derivatives
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
CN1259944A (en) 2000-07-12
ZA982819B (en) 1999-10-04
JP2001518900A (en) 2001-10-16
WO1998045288A1 (en) 1998-10-15
ID24358A (en) 2000-07-13
PL336205A1 (en) 2000-06-05
HUP0003589A3 (en) 2002-02-28
NO994903D0 (en) 1999-10-08
KR20010006218A (en) 2001-01-26
CA2286204A1 (en) 1998-10-15
EP0975629A4 (en) 2001-03-21
HUP0003589A2 (en) 2002-01-28
TR199902701T2 (en) 2000-02-21
IL132277A0 (en) 2001-03-19
NO994903L (en) 1999-12-09
AU6966198A (en) 1998-10-30
EP0975629A1 (en) 2000-02-02
BR9808515A (en) 2001-06-19

Similar Documents

Publication Publication Date Title
EA200000220A1 (en) COMBINATION OF TYROSINKINASE INHIBITOR AND CHEMICAL STERILIZATION FOR TREATMENT OF PROSTATE GLAND
DK1019060T3 (en) androgen
TR199801195T2 (en) Quinoline and quinosil compounds useful in therapy.
DE69815313D1 (en) CHINOLINE AND CHINAZOLINE COMPOUNDS OF THERAPEUTIC BENEFIT, ESPECIALLY FOR TREATING GOOD PROSTATE HYPERPLASIA
DE69809726D1 (en) SUBSTITUTED ANALOGS OF INDOL-3-CARBINOL AND DIINDOLMETHANE AS ANTIESTROGEN
DK1039912T3 (en) Angiostatic agents and preparations for the treatment of GLC1A glaucoma
AP9901478A0 (en) Compounds for the treatment of ischemia.
EA199700044A1 (en) ESTROGEN AGENTS
DK0480950T3 (en) Combination therapy for prophylaxis for and / or treatment of benign prostatic hypertrophy
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
MY112949A (en) Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia
DK279790A (en) AROMATIC STEROID-5-ALFA REDUCTASE INHIBITORS
TR199901104T2 (en) Farmas�tik bile�ikler.
EA199900914A1 (en) Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective modulators of estrogen receptors
ATE156839T1 (en) NEW DELTA-17 AND DELTA-20 UNSATURATED AND SATURATED 17--G(B)-SUBSTITUTED-4-AZA-5-G(A)- ANDROSTAN-3-ONE COMPOUNDS AS INHIBITORS OF 5-ALPHA-REDUCTASE
DE69814894T2 (en) ISOCHINOLINE DERIVATIVES AS UROKINASE INHIBITORS
IT1270993B (en) ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS
HUP0100781A2 (en) Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia and pharmaceutical compositions containing them
AR014352A1 (en) FUNGICIDE MIXTURES AND PROCEDURE TO CONTROL HARMFUL FUNGES WITH SUCH MIXTURES
EA199800058A1 (en) METHOD OF TREATMENT OF BENEFICIAL PROSTATE HYPERPLASIA, A MEDICAL FORM FOR THE TREATMENT OF BENEFICIAL HYPERPLASIA CONTAINING MELATONIN AGONIST
ATE222263T1 (en) PROSTATE-SPECIFIC ANTIGEN INHIBITORS
MX9710075A (en) Melatonin agonists for treating benign prostatic hyperplasia.
IT1265237B1 (en) Basic derivatives of indole
ITMI920850A0 (en) BENZOFURAN-IMIDAZOLES FOR USE AS AROMATISIA INHIBITORS 17,20-LIASINELLA RPOPHYLAXIS AND TREATMENT OF BREAST CANCER AND BENIGN PROSTATIC HYPERPLASIA